Evidence map›Paper›PMID 38377612›Full record

ArticleThe American journal of tropical medicine and hygiene2024

Detection of Artemisinin Resistance Marker Kelch-13 469Y in Plasmodium falciparum, South Kivu, Democratic Republic of the Congo, 2022.

Welmoed van Loon, Bertin C Bisimwa, Valéry Byela, Rebecca Kirby, Patrick M Bugeme, Aimé Balagizi, David Lupande, Espoir B Malembaka, Frank P Mockenhaupt, Esto Bahizire

Open access · greenAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Artemisinin-resistant malaria.Clinical microbiology reviews · 2024
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 4 countries.

Welmoed van LoonInstitute of International Health, Center for Global Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Bertin C BisimwaCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Valéry ByelaInstitut Supérieur des Techniques Médicales de Bukavu, Bukavu, Democratic Republic of the Congo.
Rebecca KirbyUniversity of California, San Diego School of Medicine, San Diego, California.
Patrick M BugemeCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Aimé BalagiziHôpital Général de Référence de Nyantende, Nyantende, Democratic Republic of the Congo.
David LupandeCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Espoir B MalembakaCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Frank P MockenhauptInstitute of International Health, Center for Global Health, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Esto BahizireCenter for Tropical Diseases & Global Health, Université Catholique de Bukavu, Bukavu, Democratic Republic of the Congo.
Université Catholique de Bukavu · CDBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEJohns Hopkins University · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Partial artemisinin resistance has emerged in East Africa, posing a threat to malaria control across the continent. The Democratic Republic of the Congo carries one of the heaviest malaria burdens globally, and the South Kivu province directly borders current artemisinin resistance hot spots, but indications of such resistance have not been observed so far. We assessed molecular markers of antimalarial drug resistance in 256 Plasmodium falciparum isolates collected in 2022 in South Kivu, Democratic Republic of the Congo. One isolate carried the P. falciparum Kelch-13 469Y variant, a marker associated with partial artemisinin resistance and decreased lumefantrine susceptibility in Uganda. In addition, the multidrug resistance-1 mutation pattern suggested increased lumefantrine tolerance.

Indexed as

AntimalarialsArtemisininsMalaria, FalciparumDemocratic Republic of the CongoDrug ResistanceHumansLumefantrinePlasmodium falciparumProtozoan ProteinsUgandaAntimalarialsartemisininArtemisininsLumefantrineProtozoan Proteins

Identifiers

PMID38377612
PMCPMC10993838
OpenAlexW4391951268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.